This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holten-Andersen, M. N. Articles by Brünner, N. Search for Related Content PubMed PubMed Citation Articles by Holten-Andersen, M. N. Articles by Brünner, N.

High Preoperative Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Are Associated with Short Survival of Patients with Colorectal Cancer¹

Finsen Laboratory, Rigshospitalet, DK-2100 Copenhagen, Denmark [M. N. H-A., R. W. S., I. J. C., N. B.]; Department of Surgical Gastroenterology, Hvidovre Hospital, 2650 Hvidovre, DK-2650 Denmark [H. J. N.]; School of Biological Sciences, University of East Anglia, Norwich, NR4 7T3 United Kingdom [G. M.]; and Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20892-1500 [W. S-S.]

ABSTRACT

The objective of the present study was to measure preoperative plasma tissue inhibitor of metalloproteinase (TIMP)-1 levels in colorectal cancer patients and relate these values to clinical and biochemical patient characteristics. TIMP-1 levels were determined by ELISA in EDTA plasma samples collected preoperatively from 588 colorectal cancer patients. Plasma TIMP-1 levels were distributed with a median value of 141.1 µg/liter (range, 53.7–788.7 µg/liter). Whereas no significant differences were found in the median plasma TIMP-1 levels among patients with Dukes’ stage A, B, and C disease, patients with Dukes’ stage D disease had significantly higher plasma TIMP-1 levels (P < 0.0001); however, high plasma TIMP-1 levels were not restricted to advanced disease. A relatively weak correlation between plasma TIMP-1 level and age was found (r = 0.35; P < 0.0001). There was no significant difference in TIMP-1 levels between males and females (P = 0.97). Univariate analysis demonstrated an increasing risk of mortality with increasing TIMP-1 levels [scored as the log_e(TIMP-1); hazard ratio = 3.3; 95% confidence interval, 2.6–4.2; P < 0.0001]. Including covariates (Dukes’ stage, primary tumor location, gender, age, plasminogen activator inhibitor type 1, and soluble urokinase plasminogen activator receptor) in a multivariate analysis, TIMP-1 was retained in the final model (hazard ratio = 2.5; 95% confidence interval, 1.7–3.7; P < 0.0001). This study showed a highly significant association between preoperative plasma TIMP-1 levels and survival in colorectal cancer patients, with higher plasma TIMP-1 levels being associated with poor outcome. Independent of clinical parameters including Dukes’ stage, plasma TIMP-1 levels were found to strongly predict prognosis of colorectal cancer patients. Additional studies are needed to validate the clinical usefulness of plasma TIMP-1 measurements.

This article has been cited by other articles:

				C. FREDERIKSEN, A.F. LOMHOLT, G.J. DAVIS, B.L. DOWELL, M.A. BLANKENSTEIN, I.J. CHRISTENSEN, N. BRUNNER, and H.J. NIELSEN Changes in Plasma TIMP-1 Levels after Resection for Primary Colorectal Cancer Anticancer Res, January 1, 2009; 29(1): 75 - 81. [Abstract] [Full Text] [PDF]

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				S. O. Wurtz, S. Moller, H. Mouridsen, P. B. Hertel, E. Friis, and N. Brunner Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer: A Prospective Study Mol. Cell. Proteomics, February 1, 2008; 7(2): 424 - 430. [Abstract] [Full Text] [PDF]

				Y.-S. Kim, S. Y. Hwang, H.-Y. Kang, H. Sohn, S. Oh, J.-Y. Kim, J. S. Yoo, Y. H. Kim, C.-H. Kim, J.-H. Jeon, et al. Functional Proteomics Study Reveals That N-Acetylglucosaminyltransferase V Reinforces the Invasive/Metastatic Potential of Colon Cancer through Aberrant Glycosylation on Tissue Inhibitor of Metalloproteinase- Mol. Cell. Proteomics, January 1, 2008; 7(1): 1 - 14. [Abstract] [Full Text] [PDF]

				S. Varghese, M. Burness, H. Xu, T. Beresnev, J. Pingpank, and H. R. Alexander Site-Specific Gene Expression Profiles and Novel Molecular Prognostic Factors in Patients with Lower Gastrointestinal Adenocarcinoma Diffusely Metastatic to Liver or Peritoneum Ann. Surg. Oncol., December 1, 2007; 14(12): 3460 - 3471. [Abstract] [Full Text] [PDF]

				N. M. Sorensen, P. Bystrom, I. J. Christensen, A. Berglund, H. J. Nielsen, N. Brunner, and B. Glimelius TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid Clin. Cancer Res., July 15, 2007; 13(14): 4117 - 4122. [Abstract] [Full Text] [PDF]

				M. Thaysen-Andersen, I. B. Thogersen, H. J. Nielsen, U. Lademann, N. Brunner, J. J. Enghild, and P. Hojrup Rapid and Individual-specific Glycoprofiling of the Low Abundance N-Glycosylated Protein Tissue Inhibitor of Metalloproteinases-1 Mol. Cell. Proteomics, April 1, 2007; 6(4): 638 - 647. [Abstract] [Full Text] [PDF]

				I. V. Sorensen, C. Fenger, H. Winther, N. T. Foged, U. Lademann, N. Brunner, and P. A. Usher Characterization of Anti-TIMP-1 Monoclonal Antibodies for Immunohistochemical Localization in Formalin-fixed, Paraffin-embedded Tissue J. Histochem. Cytochem., October 1, 2006; 54(10): 1075 - 1086. [Abstract] [Full Text] [PDF]

				H. Ruokolainen, P. Paakko, and T. Turpeenniemi-Hujanen Tissue Inhibitor of Matrix Metalloproteinase-1 Is Prognostic in Head and Neck Squamous Cell Carcinoma: Comparison of the Circulating and Tissue Immunoreactive Protein Clin. Cancer Res., May 1, 2005; 11(9): 3257 - 3264. [Abstract] [Full Text] [PDF]

				A.-S. Schrohl, M. N. Holten-Andersen, H. A. Peters, M. P. Look, M. E. Meijer-van Gelder, J. G. M. Klijn, N. Brunner, and J. A. Foekens Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer Clin. Cancer Res., April 1, 2004; 10(7): 2289 - 2298. [Abstract] [Full Text] [PDF]

				M. Bloomston, E. E. Zervos, and A. S. Rosemurgy II Matrix Metalloproteinases and Their Role in Pancreatic Cancer: A Review of Preclinical Studies and Clinical Trials Ann. Surg. Oncol., August 1, 2002; 9(7): 668 - 674. [Abstract] [Full Text] [PDF]

				M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen, H. Lilja, G. Murphy, V. Jensen, N. Brunner, and T. Piironen Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases 1 in Plasma by Immunoassay Clin. Chem., August 1, 2002; 48(8): 1305 - 1313. [Abstract] [Full Text] [PDF]

				T. Utsunomiya, Y. Hara, A. Kataoka, M. Morita, H. Arakawa, M. Mori, and S. Nishimura Cystatin-like Metastasis-associated Protein mRNA Expression in Human Colorectal Cancer Is Associated with Both Liver Metastasis and Patient Survival Clin. Cancer Res., August 1, 2002; 8(8): 2591 - 2594. [Abstract] [Full Text] [PDF]

				M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen, R. W. Stephens, V. Jensen, O. H. Nielsen, S. Sorensen, J. Overgaard, H. Lilja, A. Harris, et al. Total Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma Yield High Diagnostic Sensitivity and Specificity in Patients with Colon Cancer Clin. Cancer Res., January 1, 2002; 8(1): 156 - 164. [Abstract] [Full Text] [PDF]

				L. Yan and M. A. Moses A Case of Tumor Betrayal : Biphasic Effects of TIMP-1 on Burkitt's Lymphoma Am. J. Pathol., April 1, 2001; 158(4): 1185 - 1190. [Full Text] [PDF]